Open Access

HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro

  • Authors:
    • Zhongbo Du
    • Luo Li
    • Wei Sun
    • Xiao Wang
    • Yao Zhang
    • Zhixiong Chen
    • Mengjuan Yuan
    • Zhen Quan
    • Nanjing Liu
    • Yanni Hao
    • Ting Li
    • Jinhua Wang
    • Chunli Luo
    • Xiaohou Wu
  • View Affiliations

  • Published online on: April 12, 2018     https://doi.org/10.3892/ijo.2018.4370
  • Pages: 99-112
  • Copyright: © Du et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Castration-resistant prostate cancer (CRPC) continues to be a major challenge in the treatment of prostate cancer (PCa). The expression of hepatocyte cell adhesion molecule (HepaCAM), a novel tumor suppressor, is frequently downregulated or lost in PCa. Overactivated Notch signaling is involved in the development and progression of PCa, including CRPC. In this study, we found that the activities of Notch signaling were elevated, while HepaCAM expression was decreased in CRPC tissues compared with matched primary prostate cancer (PPC) tissues. In addition, HepaCAM negativity was found to be associated with a worse progression‑free survival (PFS). Furthermore, the overexpression of HepaCAM induced by transfection with a HepaCAM overexpression vector (Ad‑HepaCAM) exerted antitumor effects by decreasing the proliferation, and suppressing the invasion and migration of bicalutamide‑resistant (Bica‑R) cells and enzalutamide‑resistant (Enza‑R) cells. Importantly, we found that the antitumor effects of HepaCAM on the resistant cells were associated with the downregulation of Notch signaling. Moreover, we revealed that PF‑3084014 (a γ‑secretase inhibitor) re‑sensitized Enza‑R cells to enzalutamide, and sequential dual‑resistant (E+D‑R) cells to docetaxel. Additionally, the findings of this study demonstrated that the use of PF‑3084014 alone exerted potent antitumor effect on the resistant cells in vitro. On the whole, this study indicates that HepaCAM potentially represents a therapeutic target and PF‑3084014 may prove to a promising agent for use in the treatment of refractory PCa.
View Figures
View References

Related Articles

Journal Cover

July 2018
Volume 53 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Du, Z., Li, L., Sun, W., Wang, X., Zhang, Y., Chen, Z. ... Wu, X. (2018). HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro. International Journal of Oncology, 53, 99-112. https://doi.org/10.3892/ijo.2018.4370
MLA
Du, Z., Li, L., Sun, W., Wang, X., Zhang, Y., Chen, Z., Yuan, M., Quan, Z., Liu, N., Hao, Y., Li, T., Wang, J., Luo, C., Wu, X."HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro". International Journal of Oncology 53.1 (2018): 99-112.
Chicago
Du, Z., Li, L., Sun, W., Wang, X., Zhang, Y., Chen, Z., Yuan, M., Quan, Z., Liu, N., Hao, Y., Li, T., Wang, J., Luo, C., Wu, X."HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro". International Journal of Oncology 53, no. 1 (2018): 99-112. https://doi.org/10.3892/ijo.2018.4370